JAK2 inhibitors inevitably inhibit the normal hematopoietic function of the body, which can cause anemia, thrombocytopenia, and other adverse effects (including dizziness, headache, abdominal pain, diarrhea, and the secondary tumor). Here, JAK2 is linked to neoplasm.